Interferon-Induced Cutaneous Necrosis

Abstract

French

Background:

Due to advances in recombinant DNA technology, interferons are now readily available and are frequently used in all branches of medicine. These potent biologic response modifiers carry a number of systemic and local side effects. These cytokines are usually administered subcutaneously, and recent studies have described the occurrence of inflammation or necrosis at the site of injection.

Objective:

We report a case of cutaneous necrosis at the sites of interferon injections in a 35-year-old man treated for chronic myeloid leukemia with high, daily doses of interferon alfa. In addition, we review the existing literature on interferon-induced cutaneous necrosis and discuss preventive strategies.

Conclusion:

Cutaneous inflammation or necrosis at interferon injection sites is not uncommon. Although interferon beta-lb is most commonly responsible for this complication, it is now increasingly reported with interferon alfa. It appears to be secondary to the proinflammatory effects of these cytokines or to their unmasking of a subtle hyper-coagulable state.

Get full access to this article

View all access options for this article.

References

Luger

Schwarz

. Therapeutic uses of cytokines in dermatology. J Am Acad Dermatol 1991; 24:915–926.

Caughman

Sauder

. Pathways of inflammation. In: Arndt

LeBoit

Robinson

Wintroub

, eds. Cutaneous medicine and surgery. Philadelphia, PA: WB Saunders, 1996:141–153.

Asnis

Gaspari

. Cutaneous reactions to recombinant cytokine therapy. J Am Acad Dermatol 1995; 33:393–410.

Sasseville

Tennstedt

Lachapelle

. Allergic contact dermatitis from hydrocolloid dressings. Am J Contact Dermat 1997; 8:236–238.

Isaacs

Lindenmann

. Virus interference. I: The interferon. Proc R Soc Lond B 1957; 147:258–267.

Baron

Tyring

Fleischmann

. The interferons. Mechanisms of action and clinical applications. JAMA 1991; 266: 1375–1383.

Varga

. Recombinant cytokine treatment for scleroderma. Arch Dermatol 1997; 133:637–642.

Granstein

Flotte

Armento

. Interferons and collagen production. J Invest Dermatol 1990; 95:S75–S80.

Swerlick

. Cytokines in dermatology. Semin Dermatol 1991; 10:260–267.

10.

Quesada

Talpaz

Rios

. Clinical toxicity of interferons in cancer patients: A review. J Clin Oncol 1986; 4:234–243.

11.

Cnudde

Gharakhanian

Luboinski

. Cutaneous local necrosis following interferon injections. Int J Dermatol 1991; 30:147.

12.

Orlow

Friedman-Kien

. Cutaneous ulcerations secondary to interferon alfa therapy of Kaposi's sarcoma. Arch Dermatol 1992; 128:566.

13.

Oeda

Shinohara

. Cutaneous necrosis caused by injection of α-interferon in a patient with chronic myelogenous leukemia. Am J Hematol 1993; 44:213–214.

14.

Konohana

Hasegawa

Kobayashi

. Cutaneous ulcerations resulting from intramuscular injections of interferon alfa. J Am Acad Dermatol 1996; 35:788.

15.

Rasokat

Bendick

Wemmer

. Aseptische Haut-nekrose nach subkutaner Injektion von Interferon-α. Dtsch Med Wochenschr 1989; 114:458–460.

16.

Christian

Derriennic

Aymard

. Necrose cutanée locale après injection d'interféron alpha [Letter]. Presse Med 1993; 22:783.

17.

Mihara

Goto

Shigenaga

. Interferon therapy of C-type chronic hepatitis. Miyazakiikaishi 1993; 17:40–44 (In Japanese).

18.

Nagai

Nishikiori

Masuda

. A case of chronic myelogenous leukemia developing cutaneous ulcers during interferon-α therapy. Int J Hematol 1993; 58:129–130 (in Japanese).

19.

Akiyama

Yamada

Jidoi

. A case of cutaneous ulcers after intramuscular injections of interferon-α [Abstract]. Jpn J Dermatol. 1994; 104:436 (in Japanese).

20.

Tone

Kawana

Kinoshita

. Drug eruptions of interferon-α in patients with C-type hepatitis [Abstract]. Jpn J Dermatol 1994; 104:1047.

21.

Gaspari

. Reply to Konohana. J Am Acad Dermatol 1996; 35:789.

22.

Sheremata

Taylor

Elgart

. Severe necrotizing cutaneous lesions complicating treatment with interferon beta-lb. N Engl J Med 1995; 322:1584.

23.

Elgart

Sheremata

Ahn

. Cutaneous reactions to recombinant human interferon beta-lb: The clinical and histologic spectrum. J Am Acad Dermatol 1997; 37:553–558.

24.

Miles

Wang

Cortes

. Beta interferon therapy in patients with poor prognosis Kaposi sarcoma related to the acquired immunodeficiency syndrome. Ann Intern Med 1990; 112:582–589.

25.

The IFNB Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43:655–661.

26.

Webster

Knobler

Lublin

. Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis. J Am Acad Dermatol 1996; 34:365–367.

27.

Fruland

Sandermann

Snow

. Skin necrosis with subsequent formation of squamous cell carcinoma after subcutaneous interferon beta injection. J Am Acad Dermatol 1997; 37:488–489.

28.

Trautinger

Knobler

. More on interferon-induced cutaneous necrosis [Letter]. N Engl J Med 1996; 333:1222–1223.

29.

Sheremata

Taylor

Elgart

. Reply to Trautinger [Letter]. N Engl J Med 1966; 333:1223–1224.